东宝生物
(300239)
| 流通市值：29.37亿 | | | 总市值：29.56亿 |
| 流通股本：5.90亿 | | | 总股本：5.94亿 |
| 利润表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 营业总收入 | 622,608,106.36 | 414,692,385.37 | 190,525,037.37 | 745,307,726.02 |
| 营业总成本 | 567,526,960.73 | 375,655,075.35 | 168,542,826.28 | 679,496,993.61 |
| 其他经营收益 | | | | |
| 营业利润 | 60,168,131.33 | 41,737,525.4 | 22,586,089.08 | 59,701,396.02 |
| 利润总额 | 60,708,478.25 | 42,249,998.11 | 23,107,700.38 | 61,919,795.16 |
| 净利润 | 54,940,788.21 | 37,404,024.43 | 19,694,073.21 | 54,335,408.98 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | - | - |
| 综合收益总额 | 54,940,788.21 | 37,404,024.43 | 19,694,073.21 | 54,335,408.98 |
| 资产负债表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 流动资产: | | | | |
| 流动资产合计 | 1,117,436,347.91 | 1,156,155,439.13 | 1,134,108,970.87 | 1,148,457,546.94 |
| 非流动资产: | | | | |
| 非流动资产合计 | 1,492,959,589.02 | 1,470,312,323.57 | 1,439,858,348.85 | 1,401,228,437.34 |
| 资产总计 | 2,610,395,936.93 | 2,626,467,762.7 | 2,573,967,319.72 | 2,549,685,984.28 |
| 流动负债: | | | | |
| 流动负债合计 | 273,845,537.11 | 274,289,058.14 | 235,710,195.92 | 235,852,546.69 |
| 非流动负债: | | | | |
| 非流动负债合计 | 565,308,839.82 | 598,473,908.34 | 595,368,217.79 | 590,638,604.79 |
| 负债合计 | 839,154,376.93 | 872,762,966.48 | 831,078,413.71 | 826,491,151.48 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 1,771,241,560 | 1,753,704,796.22 | 1,742,888,906.01 | 1,723,194,832.8 |
| 股东权益合计 | 1,771,241,560 | 1,753,704,796.22 | 1,742,888,906.01 | 1,723,194,832.8 |
| 负债和股东权益合计 | 2,610,395,936.93 | 2,626,467,762.7 | 2,573,967,319.72 | 2,549,685,984.28 |
| 现金流量表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 508,652,692.16 | 331,396,308.9 | 164,793,443.74 | 690,758,939.52 |
| 经营活动现金流出小计 | 445,124,095.24 | 276,875,108.53 | 143,860,170.33 | 584,834,826.9 |
| 经营活动产生的现金流量净额 | 63,528,596.92 | 54,521,200.37 | 20,933,273.41 | 105,924,112.62 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 2,291,688,005.29 | 2,050,422,920.16 | 946,277,106.18 | 3,966,035,194.49 |
| 投资活动现金流出小计 | 2,433,661,180.95 | 2,136,347,267.95 | 991,240,875.13 | 4,039,272,782.8 |
| 投资活动产生的现金流量净额 | -141,973,175.66 | -85,924,347.79 | -44,963,768.95 | -73,237,588.31 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | - | - | - | 54,513,104.02 |
| 筹资活动现金流出小计 | 57,289,590.43 | 9,706,731.69 | 219,716.25 | 126,489,868.45 |
| 筹资活动产生的现金流量净额 | -57,289,590.43 | -9,706,731.69 | -219,716.25 | -71,976,764.43 |
| 汇率变动对现金及现金等价物的影响 | -22,327.73 | 4,166.08 | -4,320.24 | -50,573.03 |
| 现金及现金等价物净增加额 | -135,756,496.9 | -41,105,713.03 | -24,254,532.03 | -39,340,813.15 |
| 期末现金及现金等价物余额 | 323,017,571.43 | 417,668,355.3 | 434,519,536.3 | 458,774,068.33 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | -41,105,713.03 | - | -39,340,813.15 |